Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease
NCT07901933Phase 1Not yet recruiting
- Sponsor
- Cajal Therapeutics
- Start
- Nov 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in anemia comparing CTX001 plus oral iron with Placebo plus oral iron (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events at Day 36 and Incidence of Serious Treatment-Emergent Adverse Events at Day 36. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
exagamglogene autotemcel
03
Conditions
anemia
Beyond the preview
Go deeper on NCT07901933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07901933.